Background. Mycobacterium ulcerans is known to cause Buruli ulcer (BU), a necrotizing skin disease leading to extensive cutaneous and subcutaneous destruction and functional limitations. However, M. ulcerans infections are not limited to skin, and osteomyelitis, still poorly described in the literature, occurs in numerous young patients in Africa.
extensive cutaneous and subcutaneous destruction, functional limitations and disabilities. It has a large spectrum of clinical presentations, ranging from painless subcutaneous nodules to extensively undermined ulcers and disseminated forms, related partly to a delays in seeking medical-care [12, 13] . The lesions of BU are mainly due to the cytotoxic and immunosuppressive properties of the toxin secreted by M. ulcerans, known as mycolactone [14, 15] . Lesions are classified according to the clinical presentation-nonulcerative (nodule, plaque, edema) or ulcerative-and according to the cross-sectional diameter of the lesion [16] .
Until recently, treatment recommendations focused on extensive excision of the lesion and skin grafting leading to important functional and esthetic sequelae. Significant progress has been made with the demonstration of the efficacy of an 8-week course of rifampicin plus streptomycin chemotherapy [16] ; more recently, the efficacy of oral treatment with clarithromycin and rifampicin has been demonstrated in mild forms of BU [17, 18] .
However, M. ulcerans infections are not limited to skin. Osteomyelitis has been described in patients with BU in Africa, with rates ranging from 6% [1] to more than 14% [13, 19] and with young boys at increased risk [20] . Bone invasion was documented both beneath skin lesions (contiguous osteomyelitis) and also remote from them (metastatic osteomyelitis) [21] [22] [23] . Meanwhile, osteomyelitis and extensive forms have remained poorly described in the literature and excluded from most of the clinical trials. Recommendations concerning the diagnosis and management of these severe forms are scarce, and the conditions may lead to crippling disabilities and amputations [21] .
We recently published a comprehensive description and analysis of BU clinical epidemiology based on laboratory-confirmed cases [20] . In this article, we focus on BU osteomyelitis and describe in detail the demographics, clinical presentation, biological and radiological features, management, and outcome in patients with M. ulcerans osteomyelitis.
PATIENTS AND METHODS

Study Design and Definitions
This retrospective matched case-control study was conducted in the Centre de Diagnostic et de Traitement de la Lèpre et de l'Ulcère de Buruli (CDTLUB) in Pobè, Benin. The CDTLUB has treated 1819 BU cases from 2003 to 2011, of which 1257 were confirmed by polymerase chain reaction (PCR).
We reviewed all patients with PCR-confirmed M. ulcerans infection and bone involvement admitted to the CDTLUB from 2003 to December 2011. A case patient was defined as one with clinical and radiological osteomyelitis and laboratoryconfirmed M. ulcerans infection. The clinical presentation of osteomyelitis has a large spectrum, ranging from an open wound exposing fractured bone to an indolent draining fistula to local swelling and tenderness at clinical examination; physicians made the diagnosis according to their own experience [24] [25] [26] . Controls were defined as patients with PCR-confirmed BU and no bone lesions admitted to the CDTLUB during the same period. Three controls, matched for both age and sex, were randomly assigned to each case patient. Case patients and controls were identified through the CDTLUB database, prospectively created along with the notification of M. ulcerans infections to the WHO [20] .
Data Collection
Detailed patient data regarding demographic characteristics, medical history, course of present illness, clinical and radiological features, microbiological findings, management (medical and surgical treatment), and outcome were collected from the medical and laboratory records of the CDTLUB in Pobè, including the WHO BU.01 form. The BCG immunization status was established by the presence or the absence of a scar on the left forearm. Additional data regarding PCR analysis were collected from the records of the microbiological laboratory of Angers, France. When available, we reviewed digital photographs of the skin lesions of the case patients at the time of admission and during follow-up. All radiographs were reviewed by experienced radiologists in France (A. R. and A. T.). Data were collected using Epidata software (version 3.0; The EpiData Association).
Laboratory Methods
Biological samples (swab, fine needle aspiration, and skin and bone biopsy) were collected and handled according to WHO guidelines [27] . M. ulcerans infection was confirmed by IS2404 PCR analysis for all patients included in the study. Routine laboratory tests (complete blood count, erythrocyte sedimentation rate and human immunodeficiency virus testing) were performed in the laboratory of the CDTLUB. Radiographs were obtained in local hospitals.
Statistical Analysis
Continuous variables were summarized using medians and interquartile ranges (IQRs), and categorical variables were summarized using frequencies and percentages with their 95% confidence intervals (CIs). The data consisted of individually matched sets with 1 case patient and 3 controls. P values for the comparisons of categorical variables between case patients and controls were obtained using conditional logistic regression analysis. Matched sets were dropped from the analysis if no data were available for the case patient or for all 3 controls. Continuous variables (eg, hemoglobin level) were compared using linear regression analysis, after log transformation when not normally distributed, adjusted for age and sex. Variables were compared among subgroups of case patients using Fisher exact, Mann-Whitney and Kruskal-Wallis tests, where appropriate. Statistical significance was set at the 5% level (2-sided P value). Analyses were conducted using Stata software (version 12.0; StataCorp).
RESULTS
Description of Patients With Osteomyelitis
From 2003 to 2011, a total of 80 patients with PCR-confirmed BU with osteomyelitis were identified from the database of the CDTLUB. They were age-and sex-matched with 240 controls without osteomyelitis. Of these 80 case patients, 2 were excluded after review of the paper files because of insufficient documentation of osteomyelitis, and 4 were considered not to have osteomyelitis; a total of 74 patients with osteomyelitis (5.9%; 95% CI, 4.6%-7.2%) were thus identified from the database. Of the 240 controls, 9 (3.7%; 95% CI, 5.4%-12.6%) were found to have bone lesions and were reclassified as case patients with osteomyelitis. New age-and sex-matched controls were randomly assigned to these 9 new case patients. Two patients with BU with osteomyelitis also had malum perforans pedis related to leprosy and were excluded from the case-control analysis. Altogether, 81 patients with osteomyelitis and their 243 controls were kept for the analysis presented herein.
The case patients had a median (IQR) age of 11 (7-16) years and were predominantly male (male-female ratio, 2:1). The median (IQR) time from symptom onset to the first hospital visit was 40 (12-52) weeks, and 19 (23.7%) patients waited for more than a year. All of them (100%) had a complex treatment history, including traditional healing (91.4%), inappropriate antibiotics (38.3%), or inappropriate minor surgery (40.7%) ( Table 1) . At the first visit, 9 patients (11.1%) were malnourished, 9 (11.1%) had a history of fever, and 32 (39.5%) had local pain. Osteomyelitis was located on the lower limbs in 51 patients (63.0%). Regional lymphadenopathy was documented in 36 (44.4%) patients, And limited function and movement in 71 (87.6%) ( Table 1) .
Overall, 49 osteomyelitis lesions (60.5%) occurred beneath typical BU skin lesions, and these patients were considered to have contiguous osteomyelitis. In 4 instances, the BU skin lesion was no longer active, but the scar and the history were typical of past BU. The cross-sectional diameter of the BU lesions exhibited by patients with contiguous osteomyelitis was larger than that in controls, with lesions >15 cm in 27 case patients (61.4%) versus 41 controls (28.9%; P < .001). Twelve patients (14.8%) had bone lesions distant from either an active (n = 6) or a past (n = 6) BU skin lesion, and were considered to have metastatic osteomyelitis, and 20 patients (24.7%) had no visible active or past BU lesion. The skin lesions observed next to the bone lesions in these patients were comparable to those observed in nonspecific osteomyelitis. These patients were considered to have exclusive osteomyelitis. Table 2 shows characteristics of the skin lesions contiguous to osteomyelitis documented at the first visit in these 3 categories of patients.
All case patients included in the study had M. ulcerans infection confirmed with PCR, with PCR testing of a bone biopsy specimen in 31 case patients (43.1%), of pus from the fistula in 5 (6.9%), and of skin biopsy, fine needle aspiration, or swab specimens of the skin lesion contiguous to the bone infection in 36 (50.0%); the origin of the positive PCR specimen was not specified in 9 patients (Supplementary Table 1 ). For the 20 case patients categorized as having exclusive osteomyelitis, the diagnosis of M. ulcerans infection was based on PCR testing of pus from the fistula (n = 2), bone biopsy specimens (n = 10), or swab specimens of nonspecific skin lesions (n = 8).
The diagnosis of osteomyelitis with radiography preceded initiation of treatment in 53 patients (63.4%). For the remaining 28 patients, radiographic diagnosis took place a median (IQR) of 25.5 (3-56.5) days after initiation of treatment. The vast majority of these patients with delayed diagnosis (n = 24; 86%) had contiguous osteomyelitis, and 4 had metastatic (n = 3) or exclusive (n = 1) osteomyelitis. Seventeen patients (21.0%) had multiple bone lesions. Metastatic bone lesions appeared after antibiotics were started in 5 patients, and the median time from the first day of treatment to the diagnosis of the first metastatic bone lesion was 88 days. A total of 99 radiographs from 76 patients were reviewed (Supplementary Table 2 ); they revealed features of chronic (75.8%) and extensive (56.6%, affecting >30% of the bone surface) lesions, located predominantly on long bones and inferior limbs (Figure 1 ). Table 1 shows demographic characteristics, underlying conditions, and history of the present illness in the 81 case patients with osteomyelitis and 243 age-and sex-matched control subjects included in the analysis. Human immunodeficiency virus (2 controls vs no case patients) was not associated with bone lesions in this cohort. Case patients were less likely to have received BCG immunization than controls (33.3% vs 52.7%; P = .01) and more likely to have a history of BU (14.8% vs 2.1%; P = .001). Patients with bone lesions had waited longer before coming to the CDTLUB or affiliated primary healthcare centers (P = .001) and during that time were more likely to have sought traditional healing or received inappropriate antibiotics or minor surgical interventions (P = .001).
Case-Control Analysis
Clinical features of the patients and descriptions of the main lesions are presented in Table 1 . Patients with bone lesions controls were more likely than controls to have functional limitations (87.6% vs 45.7%, respectively; P < .001) and multifocal lesions (33.3% vs 2.9%; P < .001). The M. ulcerans infection was confirmed in all case patients and controls by PCR of a swab, fine needle aspiration, or biopsy (skin or bone) specimen (Supplementary Table 1 ). The median time to biological confirmation was longer for case patients than for controls (7 vs 1 days, respectively; P = .001). c Twenty of 81 matched groups were dropped from the conditional logistic regression analysis because of missing data.
d Defined as the presence of a stellate scar suggestive of past BU or medical history of a prior BU.
e One of 81 matched groups was dropped from the conditional logistic regression analysis because of missing data.
f Five of 81 matched groups were dropped from the conditional logistic regression analysis because of missing data.
g Abscess, fistula, back, buttocks and perineum, head, and neck.
Routine laboratory tests showed that patients with osteomyelitis were more likely than controls to present with anemia and elevated white blood cell counts (Supplementary Table 3 ). The other hematological features were similar in both groups.
All patients were managed according to the WHO recommendations with adapted wound care and physiotherapy to prevent disability. Case patients were more likely than controls to be hospitalized (96.3% vs 64.2%; P = .001), and for a longer median duration (118 vs 69 days; P = .001). The management of patients with osteomyelitis was more complex; they received more frequently additional antibiotics (44.4% vs 11.5%; P = .001) and underwent surgery more frequently (92.6% vs 63.0%; P = .001) (Table 3, Figure 1 , and Supplementary Figure 1) .
Patients with bone lesions were less likely to recover from functional limitations than those with no bone lesions (28.8% vs 72.1%; P = .001). Treatment failure-defined as the absence of healing at a long-term follow-up visit in a patient who received appropriate medical treatment and/or underwent surgery-was more common in case patients than in controls (7.9% vs 1.6%; P = .05).
DISCUSSION
This is the first systematic retrospective analysis of bone lesions in a large cohort of 1257 PCR-confirmed M. ulcerans infections. The analysis in our 81 case patients shows that osteomyelitis can be observed beneath active BU lesions or at a distance from active or apparently healed BU lesions but also in patents without any apparent history of BU skin lesions. These lesions have an insidious course with nonspecific clinical features, which often leads to delayed diagnosis. The management of patients with bone lesions is complex; they tend to have longer hospital stays and higher risks of surgery and long-term crippling sequelae than patients with BU without osteomyelitis. It is not clear how M. ulcerans infects bones. Indeed, bone localization and metastatic spread of M. ulcerans are surprising, considering that this agent grows optimally at 30°-33°C. Certain isolates of M. ulcerans seem to be more thermotolerant [28] , and strains recovered from bone lesions in this study will be sequenced for comparison with strains obtained from skin lesions. As described in other studies, contiguous bone infection develops by direct spread of M. ulcerans from an overlying BU skin lesion that is most frequently large and ulcerative [21] . Minor trauma has also been suggested as a risk factor for nonspecific osteomyelitis, and patients with osteomyelitis in our study were more likely than controls to have experienced recent trauma. Microtrauma in the bone medulla could facilitate the local infection. Metastatic M. ulcerans osteomyelitis-bone infections developing remotely from an active or apparently healed BU, as metastatic skin lesions-are believed to result from lymphohematogenous dissemination of the mycobacteria from skin lesions. The fact that bone lesions were frequently observed on the metaphysis of bones reinforces this hypothesis. Also coinciding with this hypothesis, patients with bone infection were more likely to have multifocal lesions. Thus, once the bacteria spreads in the bloodstream, it is likely to disseminate to multiple sites. Therefore, BU should be considered a potentially systemic disease, and clinicians should search for other sites once a single focus is identified [12, 22, 23, 29] .
In this study, in addition to these known presentations of M. ulcerans osteomyelitis, we identified patients (25% of all patients with osteomyelitis) who had no evidence of past or present BU skin lesions. This seems to be a third category of M. ulcerans osteomyelitis, which we called exclusive osteomyelitis. The skin lesions of these patients were those of nonspecific osteomyelitis (eg, tumefaction, edema, and fistula) [25, 30] , and had none of the characteristics of BU skin lesions (eg, painless nodule, plaque or undermined ulcer) [16] . These case patients may have been in contact with M. ulcerans in the past and the primary infection may have gone unnoticed. The delayed appearance of a bone lesion would then result from reactivation of a latent infection, as was also suggested for the development of bone lesions beneath or distant from healed BU lesions [31] . Although the diagnosis of M. ulcerans infection may be missed in patients with exclusive osteomyelitis owing to the absence of BU lesions, the patients in this study with M. ulcerans osteomyelitis had similar delays to diagnosis, radiographic bone lesions, response to treatment, and outcomes regardless of the osteomyelitis form, exclusive, contiguous, or metastatic.
Overall, M. ulcerans osteomyelitis has a long-standing indolent course and therefore shares common demographic Figure 1 . Clinical and radiological evolution during 1 year of chronic Mycobacterium ulcerans osteomyelitis of the right tibia in a 10-year old boy. A, Buruli ulcer of the right leg with contiguous tibia osteomyelitis; the radiograph shows a sequestrum with destruction of the metaphsysis. B, C, Clinical and radiological evolution at 3 and 10 months respectively. The patient received an 8-week antibiotic regimen (streptomycin and rifampicin) and underwent surgery (skin and bone debridement with sequestrectomy).
(age and sex ratio), clinical, and radiological features with osteomyelitis linked to more frequent pathogens that are a major healthcare burden in low-income countries [25, 30, 32, 33] . Thus, a high index of suspicion for M. ulcerans should be maintained for all patients with subacute or chronic osteomyelitis in highly BU-endemic areas.
In concordance with previous findings, patients with bone infections had long and complex health-seeking itineraries and most of them combined elements of both biomedical and traditional therapeutic approaches. Buruli ulcer mainly affects rural populations with both limited geographic and financial access to health services and strong mystical beliefs. This combination of factors results in delayed medical care seeking until advanced clinical forms of the disease occur, including extensive skin destruction, multifocal lesions, and bone lesions [13, 34] . Another consequence of delayed treatment is the development of dead bone in skeletal lesions. This avascular tissue makes antibiotics essentially ineffective, and radical debridement down to living bone is therefore essential for healing [30] . Moreover, M. ulcerans osteomyelitis affects young patients who are at risk of late complications caused by the growth and developmental disturbances of the affected bone. Involvement of the epiphyseal growth cartilage incurs a high risk of subsequent growth deformity. Early identification from radiographs, appropriate antimicrobial treatment, proper debridement of the infected bone, and clinical and radiological follow-up should limit the burden of disease in this specific population [26] . Fewer case patients than controls had a history of BCG vaccination. This is consistent with previous studies showing that BCG vaccination conferred some protection against severe forms of BU, such as osteomyelitis [19, 35] , but induced only transient protective immunity against the development of skin lesions [36] . The prophylactic effect of BCG on severe and disseminated forms of BU has not been clearly explained so far but is reminiscent of the protective effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis [37] .
In conclusion, this study allowed the identification of a third form of M. ulcerans osteomyelitis in patients with no evidence of active or past BU disease, which we called exclusive osteomyelitis. Physicians working in BU-endemic areas should be aware of the existence of this form of disease and actively search for M. ulcerans confirmation when dealing with patients with osteomyelitis, even in the absence of BU skin lesions. We also highlight the importance of early identification of bone lesions leading to appropriate antibiomicrobial treatment, surgery, adapted physiotherapy, and clinical and radiological follow-up to prevent infection dissemination and extensive skin and bone destruction and therefore reduce functional limitation and disability.
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